Her-HsinTsai, MD, FRCP, FECG

Consultant Physician and Gastroenterologist
Hull and East Yorkshire NHS Hospital Trusts
Hull Royal Infirmary
Anlaby Rd, Hull
East Riding of Yorkshire HU3 2JZ, UK



• M.B.; Ch. B. with Commendation (July 1983)
• Member of the Royal College of Physicians (U.K.)
1. M.R.C.P. (U.K.) Part 1 (Feb. 1985) first attempt
2. M.R.C.P. (U.K.) Part 2 (Feb. 1986) first attempt
• Doctor of Medicine (M.D.) with Honours
o M.D. thesis entitled: faecal mucin sulphatase: identification, purification and characterisation of a novel enzyme and its relevance to ulcerative colitis.


• GRADE:House Officer (Aberdeen Teaching Hospitals)
o 1.8.83-31.1.84 General Surgery
o 1.2.84-31.7.84 General Medicine/ Haematology
• GRADE: Senior House Officer (Aberdeen Teaching Hospitals)
o 1.8.84-30.9.84 Dermatology
o 1.10.84-30.11.84 Psychiatry
o 1.12.84-31.1.85 Coronary Care Unit
o 1.2.85-31.4.85 General Medicine/ Renal Medicine
o 1.5.85-31.7.85 General Medicine/ Endocrinology and Diabetes
• GRADE: Registrar (Aberdeen Teaching Hospitals)
o 1.8.85-31.1.86 General Medicine/ Clinical Oncology
o 1.2.86-31.7.86 Rheumatology/ Infectious Diseases
o 1.7.86-15.1.87 General Medicine/ Cardiology
• GRADE: Registrar in Gastroenterology (University Department of Materia Medica, Stobhill General Hospital, GLASGOW)
o 15.1.87-31.7.89 General Medicine
o 15.1.87-31.7.89 Gastroenterology
• GRADE: Research Fellow/Honorary Registrar In Gastroenterology (Department of Medicine, University of Liverpool)
o 1.9.89 – 31.3.91 Research
o 1.9.89 – 31.3.91 Clinical
• GRADE: Clinical Lecturer in Medicine and Hon. Senior registrar (Department of Medicine, University of Liverpool
o 1.4.91 to 31.7.91 General Medicine
o 1.4.91 to 31.7.91 GI Medicine
o 1.4.91 to 31.7.91 Teaching
• 1.7.91to 12.4.94: Senior Registrar in Medicine and Gastroenterology, Liverpool Rotation: Royal Liverpool University Hospital
• 12.9.94to present: Consultant Physician and Gastroenterologist, Hull and East Yorkshire NHS Hospital Trusts

Research Interest

His research interests include: Epidemiology and epigenetics of inflammatory bowel diseases.

Scientific Activities


• Alexander Smith Cardno Prize (1979): Anatomy
• Fyfe Jamieson Gold Medal (1979): Anatomy
• McWillie Prize (1980): Physiology and Biochemistry
• Durno Prize (1980): Anatomy
Munday and Venn Prize (1980): Most Distinguished Student
• MacQuibbon Prize (1983): Medicine and Medical Specialities
• Shephard Gold Medal (1983): Clinical Surgery
• Anderson Prize (ProximaAccesit) (1983): Clinical Medicine
• Medical Protection Society Prize (1983): Best Original Elective
• Watt and Grant Bursary (1979, 1980, 1981 and 1982): Distinguished Performance
• John Hunter Bursary (1979, 1980, 1981, and 1982): Distinguished Performance


1. Tsai HH, Suryawanshi N. Ocular complications of leprosy in Karagiri, South India. Leprosy Review. 1985; 56: 135-141.
2. Tsai HH, Eastmond C J. Modified costotransversectomy in the treatment of intractable pain in ankylosing spondylosis. British Journal of Rheumatology. 1987; 21: 66-67.
3. Tsai HH, Howden CW, Thomson TJ. Probable Crohn; s disease mimicking ischaemic colitis in a young adult. Scottish Medical Journal. 1989; 34: 406-407.
4. Tsai HH. Dugald Christie: Scottish medical pioneer in Manchuria (1883-1923). Scottish Medical Journal. 1989; 34: 443-444.
5. Tsai HH, Lees KR, Howden CW, Reid JL The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis. British Journal of Clinical Pharmacology. 1989; 28: 53-59.
6. Howden CW, Tsai HH. (24-hour intragastric acidity in duodenal ulcer patients treated with ranitidine 150 mg twice daily, 150 mg four times daily and placebo. Alimentary Pharmacology and Therapeutics. 1989; 3: 253-258.
7. Tsai HH, Moir K, Thomson AH, Howden CW, Danesh BJZ. The prevalence and significance of digoxin-like immunoreactive substances in liver disease. European Journal of Gastroenterology and Hepatology. 1989; 1: 201-203.
8. Tsai HH, Smith J, Danesh BJ. Successful control of bleeding from gastric antral vascular ectasia (watermelon stomach) by laser photocoagulation. Gut. 1991; 32: 92-94.
9. Tsai HH. Statistical analyses of enzyme inhibitor kinetics: A hierarchical model-dependent method. Biochemistry International. 1991; 23: 75-81.
10. Tsai HH. A case of watermelon-stomach treated with heat-probe electrocoagulation. (letter) Gut. 1991; 32: 964.
11. Tsai HH, Hart CA, Rhodes JM. Production of mucin degrading sulphatase and glycosidases by Bacteroid esthetaiotao micron. Letters in Applied Microbiology. 1991; 13: 97-101.
12. Tsai HH. Scottish Women Medical Pioneers: Manchuria 1894-1912. Scottish Medical Journal. 1992; 37: 56-59.
13. Tsai HH. Treatment of Watermelon Stomach by laser photocoagulation. Gastroenterology Digest. 1992; 4: 12-14.
14. Tsai HH, Rhodes JM. Mucus, Bacteria and Colitis. Saudi Medical Journal. 1992; 13(3): 180-188.
15. Tsai HH, Sunderland D, Gibson G, Hart CA, Rhodes JM. A Novel MucinSulphatase from Human Faeces: Its Identification, Purification and Characterisation. Clinical Science. 1992; 82: 447-454.
16. Tsai HH, Lees KR, Danesh BJZ, Reid JL. Effect of Acute and Chronic Dosing of Perindopril in Renal Water and Salt Handling in Patients with Compensated Hepatic Cirrhosis. Europ J Gastroenterol Hepatol. 1992; 4: 289-294.
17. Parker N, Tsai HH, Ryder SD, Raouf AH, Rhodes JM. Increased sialylation of colonic mucin in ulcerative colitis. Dig Dis Sci. 1993.
18. Raouf AH, Tsai HH, Parker N, Hoffman J, Walker RJ, Rhodes JM. Sulphation of colonic and rectal mucin in inflammatory bowel disease: reduced sulphation of rectal mucus in ulcerative colitis. Clinical Science. 1992; 83: 623-626.
19. Tsai HH& Rhodes JM. Mucus Glycoprotein Alterations in Inflammatory Bowel Disease. Europ J GastroenterolHepatol. 1993; 5: 214-218.
20. Parker N, Raouf AH, Ryder SD, Finnie IA, Tsai HH, Milton JD, Rhodes JM. High performance gel filtration using a monodisperse agarose column by a one-step method for purifying mucus glycoprotein. Biomedical Chromatography. 1993; 7: 68-74.
21. Tsai HH, Dwarkanath AW, Hart CA, Rhodes JM. Feacal Mucin Sulphatase Activity in Patients with inflammatory bowel disease: A potential new target for therapy. Gut. 1995; 36: 570-576.
22. Dwarakanath AD, Campbell BJ, Tsai HH, Hart CA, Rhodes JM. Faecal mucinase activity assessed in imflammatory bowel disease by using human 14C Threonine-labelled mucinsubstrste. Gut. 1995; 37: 58-62. 23. Dwarakanath AD, Crabtree JE, Figura N, Tsai HH, Hart CA, Rhodes JM. Production of neuraminadase and fucosidase by Helicobacter pylori: Possible relationship with pathogenesis. FEMS ImmunolMicrobacteriol. 1995; 12: 213-216. doi: 10.1111/j.1574-695X.1995.tb00194.x
24. Tsai HH, Hart CA, Rhodes JM. Production of mucin degrading sulphatase and glycosidases by Bacteroides thetaiotaomicron. Letters in Applied Microbiology. 1991; 13: 97-101.
25. Tsai HH, Dwarakanath AD, Hart CA, et al. Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment. Gut. 1995; 36: 570-576 .
26. Jameel JKA, Pillinger SH, Moncur P, Tsai HH, Duthie GS. Endoscopic mucosal resection (EMR) in the management of large colo-rectal polyps. Colorectal Disease. 2006; 8: 497-500. doi: 10.1111/j.1463-1318.2006.00966.x
27. Verma S, Tsai HH, Giaffer MH. Does Better Disease-Related Education Improve Quality of Life? Digestive diseases and sciences. 2001; 46(4): 865-869.
28. Tsai HH. Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study. Alimentary pharmacology & therapeutics. 2004; 20(6): 657-665. doi: 10.1111/j.1365-2036.2004.02155.x
29. Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long‐term cost effectiveness of scheduled maintenance treatment with infliximab for moderate‐to‐severe ulcerative colitis. Alimentary pharmacology & therapeutics. 2008; 28(10): 1230-1239. doi: 10.1111/j.1365-2036.2008.03839.x
30. Russo EA, Harris AW, Campbell S, et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Alimentary Pharmacology & Therapeutics. 2009; 29: 308-314. doi: 10.1111/j.1365-2036.2008.03890.x.
31. Corless L, Tsai H. Primary Sclerosing Cholangitis-Current Issues in Clinical Practice. Open Pharmacology Journal. 2012; 6: 45-51. doi: 10.1111/j.1365-2036.2005.02407.x
32. Thayalasekaren S, Tsai HH. Novel therapies for Constipation. World Journal of Gastroenterology. 2013; 19(45): 8247-8251. doi: 10.3748/wjg.v19.i45.8247.
33. Wong LL Tsai HH. Prophylaxis for post-ERCP induced pancreatitis. World Journal of gastrointestinal Pathophysiology. 2014; 5(1): 1-10. doi: 10.4291/wjgp.v5.i1.1.
34. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe – An ECCO-EpiCom study. EpiCom-group. J Crohns Colitis. 2014; 8(7): 607-616. doi: 10.1016/j.crohns.2013.11.021.
35. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. EpiCom Group. Inflamm Bowel Dis. 2014; 20(1): 36-46. doi: 10.1097/01.MIB.0000436277.13917.c4.
36. Tsai HH. Magnetic resonance elastography comes of age. Liver Res Open J. 2015; 1(2): e4-e5. doi: 10.17140/LROJ-1-e002